Z-0921-2025 Class II Ongoing

Recalled by DRG International, Inc. — Springfield, NJ

FDA device recall Z-0921-2025 was initiated by DRG International, Inc. on Oct 7, 2024 and is designated Class II. Reason for recall: The user of the assay may either face a failure message during re-calibration of the Hybrid.XL instrument using the re-calibration R1 and R2 of the device or find controls out of specification (failed… The recall status is ongoing. Affected quantity: 10 units.

Recall details

Product Type
Devices
Report Date
Jan 22, 2025
Initiation Date
Oct 7, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
10 units

Product description

DRG:HYBRiD-XL Insulin. Model/Catalog Number: HYE-5361

Reason for recall

The user of the assay may either face a failure message during re-calibration of the Hybrid.XL instrument using the re-calibration R1 and R2 of the device or find controls out of specification (failed Control High) which causes a delay in results.

Distribution pattern

Worldwide - US Nationwide distribution in the state of New Jersey and the countries of Czechia and Romania.

Code information

UDI: (01)04048474053616(17)20251130(10)429K084-1. Lot Number: 429K084-1

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-0921-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-0921-2025. Report a data issue: hello@regdatalab.com.